Immediate Impact
19 standout
Citing Papers
Cancer statistics, 2025
2025 Standout
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
Works of Jad Bsat being referenced
A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jad Bsat | 44 | 62 | 32 | 3 | 66 | |
| Sandra Le Guyader-Peyrou | 32 | 54 | 38 | 5 | 74 | |
| Moulod R. El-Agnaf | 40 | 33 | 22 | 4 | 81 | |
| G.K. Bascom | 16 | 41 | 27 | 2 | 63 | |
| Yunhang Guo | 37 | 29 | 11 | 4 | 64 | |
| Diego Cortese | 80 | 58 | 9 | 3 | 94 | |
| Katya Ahr | 15 | 28 | 20 | 4 | 44 | |
| Claire Saule | 54 | 27 | 13 | 5 | 71 | |
| Joe Sneath Thompson | 12 | 36 | 19 | 3 | 48 | |
| Ruzena Uddin | 29 | 68 | 56 | 2 | 77 | |
| Sabrina Kless | 72 | 57 | 11 | 4 | 73 |
All Works
Loading papers...